Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Guardant Health (GH – Research Report), with a price ...

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Guardant Health (NASDAQ:GH – Get Free Report) had its price target increased by equities research analysts at Stifel Nicolaus ...

Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions ...

Guardant Health is a leader in liquid biopsy. It has market leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer ...